On February 28, 2022 Immune-Onc Therapeutics, Inc. ("Immune-Onc"), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints, reported that Charlene Liao, Ph.D., chief executive officer of Immune-Onc, will host virtual one-on-one investor meetings at the Cowen 42nd Annual Health Care Conference and will deliver a company presentation at the Oppenheimer 32nd Annual Healthcare Conference (Press release, Immune-Onc Therapeutics, FEB 28, 2022, View Source [SID1234609166]). Details of the conferences are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cowen 42nd Annual Health Care Conference (March 7-9, 2022)

Immune-Onc will be scheduling virtual one-on-one investor meetings as a private company. Meetings may be requested through Cowen.
Oppenheimer 32nd Annual Healthcare Conference (March 15-17, 2022)

Immune-Onc will present a corporate overview on Wednesday, March 16, 2022, at 4:40 PM – 5:10 PM ET (Track 6) and will participate in virtual one-on-one meetings. Please contact your Oppenheimer representative to schedule.